Back to top
more

Enovis (ENOV)

(Delayed Data from NYSE)

$45.40 USD

45.40
577,637

-1.14 (-2.45%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $45.43 +0.03 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (156 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Standard BioTools (LAB) delivered earnings and revenue surprises of -33.33% and 22.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?

by Debanjana Dey

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares

by Zacks Equity Research

Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.

Zacks.com featured highlights include Energizer, Super League Enterprise and Enovis

by Zacks Equity Research

Energizer, Super League Enterprise and Enovis have been highlighted in this Screen of The Week article.

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

by Zacks Equity Research

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Sanghamitra Saha headshot

Bet on 3 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Energizer (ENR), Super League Enterprise Inc. (SLE) and Enovis (ENOV).

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?

by Zacks Equity Research

Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Nalak Das headshot

5 Medical Info Systems Stock to Buy for a Stable Portfolio

by Nalak Das

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.

Ensign Group (ENSG) Buys Facilities in Arizona & Colorado

by Zacks Equity Research

Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.

Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst

by Zacks Equity Research

Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

Nalak Das headshot

5 Medical Info Systems Stocks to Buy for Stable Returns

by Nalak Das

We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

Here's Why Enovis (ENOV) is Poised for a Turnaround After Losing -17.45% in 4 Weeks

by Zacks Equity Research

Enovis (ENOV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -15.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Enovis (ENOV)

by Zacks Equity Research

Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Enovis (ENOV) Q1 Earnings Match Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biotricity Inc. (BTCY) delivered earnings and revenue surprises of 17.07% and 0.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.28% and 2.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now

by Zacks Equity Research

Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

by Zacks Equity Research

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Why Community Health (CYH) Shares Are Attracting Investors Now

by Zacks Equity Research

We expect Community Health's (CYH) occupancy rate to continue moving upward, reflecting improving utilization of its facilities and services.

Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada

by Zacks Equity Research

The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.

Reasons to Retain HCA Healthcare (HCA) Stock in Your Portfolio

by Zacks Equity Research

HCA Healthcare's (HCA) improving top line, acquisition initiatives and a robust growth outlook poise the company well for growth.